GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Total Current Liabilities
中文

Aravive (Aravive) Total Current Liabilities

: $9.78 Mil (As of Sep. 2023)
View and export this data going back to 2014. Start your Free Trial

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Aravive's total current liabilities for the quarter that ended in Sep. 2023 was $9.78

Aravive Total Current Liabilities Historical Data

The historical data trend for Aravive's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 4.97 9.46 17.94 22.11

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.73 22.11 20.19 14.22 9.78

Aravive Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Aravive's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.503+2.195
+Other Current Liabilities+Current Deferred Liabilities
=-3.5527136788005E-15+4.414
=22.11

Aravive's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.656+2.121
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=9.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Aravive Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Aravive's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (Aravive) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Total Current Liabilities
Comparable Companies
BNTC VYNE ONVO ENZN CMRA INTI GRTX VIRI BRTX TMBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
VE11:Germany VE11:Germany
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Website
https://www.aravive.com
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines

From GuruFocus

Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023

By Marketwired • 07-14-2023

Aravive Appoints Rudy Howard as Chief Financial Officer

By GuruFocusNews GuruFocusNews • 07-03-2022

Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer

By sperokesalga sperokesalga • 02-28-2023

Aravive to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 06-26-2022

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

By PurpleRose PurpleRose • 07-11-2022

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

By sperokesalga sperokesalga • 05-25-2023

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

By GuruFocusNews GuruFocusNews • 07-01-2022

Aravive Announces Approximately $41.5 Million Private Placement Financing

By Value_Insider Value_Insider • 10-25-2022

Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium

By sperokesalga sperokesalga • 02-13-2023

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

By Value_Insider Value_Insider • 11-10-2022